Table 3.
Multivariate analysis, using the compound age/test classification attribute for the DC and the VC.
| Development Cohort | |||||
|---|---|---|---|---|---|
| OS | PFS | ||||
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | ||
| ProteomicAgeClassification | 0.68 (0.56–0.83) | <0.001 | 0.85 (0.73–1.00) | 0.047 | |
| FIGO (vs. IV) | I/II | 0.17 (0.07–0.42) | <0.001 | 0.08 (0.03–0.21) | <0.001 |
| III | 0.46 (0.28–0.75) | 0.002 | 0.51 (0.30–0.84) | 0.009 | |
| Histology (vs. serous) | non-serous | 1.53 (0.94–2.48) | 0.087 | 1.71 (1.04–2.81) | 0.034 |
| Grade (vs. 3) | 1/2 | 0.97 (0.62–1.50) | 0.881 | 1.35 (0.88–2.09) | 0.171 |
| Residual Tumor (vs. yes) | no | 1.71 (1.06–2.77) | 0.028 | 1.67 (1.05–2.64) | 0.029 |
| Validation Cohort | |||||
| OS | PFS | ||||
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | ||
| ProteomicAgeClassification | 0.81 (0.67–1.00) | 0.045 | 0.83 (0.70–0.98) | 0.030 | |
| FIGO (vs. IV) | I/II | 0.62 (0.19–2.01) | 0.428 | 0.26 (0.07–0.94) | 0.040 |
| III | 0.49 (0.28–0.84) | 0.010 | 0.56 (0.32–0.96) | 0.035 | |
| Histology (vs. serous) | 0.88 (0.45–1.69) | 0.695 | 0.79 (0.43–1.46) | 0.458 | |
| Grade (vs. 3) | 1/2 | 0.99 (0.56–1.76) | 0.981 | 0.95 (0.58–1.54) | 0.835 |
| Residual Tumor (vs. yes) | no | 2.20 (1.33–3.65) | 0.002 | 1.74 (1.03–2.95) | 0.039 |